A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two ...

One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics ( GPCR 0.16%), was a victim of a ...

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

Results showed that people craved and drank less alcohol when on the drug, according to the findings of a recent study.

Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...

Novo Nordisk A/S failed to convince a federal judge that a pharmacy in Florida making compounded versions of its diabetes and ...